|
|||||
|
Boston Scientific Announces Suit By Johnson & Johnson |
|||||
| |
|||||
NATICK, Mass., Jan. 14 -- Boston Scientific Corporation (NYSE: BSX - News) announced today that Cordis Corporation, a subsidiary of Johnson & Johnson, has filed a suit in the United States District Court for the District of Delaware alleging that Boston Scientific stents, including the Express2(TM) stent, willfully infringe a patent owned by Cordis. The suit seeks a declaration of validity and infringement of the patent, and injunctive and monetary relief. The District Court set aside earlier this year a verdict finding infringement of the same patent against the NIR® stent sold by Boston Scientific. Boston Scientific believes that its stents, particularly the Express2(TM) stent, do not infringe the patent and that the allegations in the suit are without merit. Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices. Its products are used in a broad range of interventional medical specialties. without merit. This press release contains forward-looking statements. Boston Scientific wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the litigation process, commercialization of technologies, competitive offerings, intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.
|